Global manufacturer of aliphatic amines, amine derivatives and specialty chemicals for pharma & agro.
Price
Market Cap
Sector
Commodities
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves | 526 | 782 | 980 | 1.2k | 1.3k | 1.4k | 1.4k | 1.5k |
| Borrowings | 87 | 47 | 23 | 88 | 3 | 6 | 2 | 1 |
| Other Liabilities | 160 | 306 | 359 | 335 | 314 | 381 | 322 | 362 |
| Total Liabilities | 783 | 1.1k | 1.4k | 1.6k | 1.6k | 1.8k | 1.8k | 1.9k |
| AssetsFixed Assets | 423 | 458 | 629 | 719 | 1.1k | 1.0k | 1.0k | 1.0k |
| CWIP | 45 | 138 | 143 | 352 | 36 | 52 | 76 | 130 |
| Investments | 0 | 30 | 0 | 0 | 0 | 0 | 0 | 51 |
| Other Assets | 315 | 520 | 600 | 521 | 459 | 693 | 651 | 700 |
| Total Assets | 783 | 1.1k | 1.4k | 1.6k | 1.6k | 1.8k | 1.8k | 1.9k |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 144 | 188 | 364 | 205 | 248 | 275 | 263 | 239 |
| Cash from Investing | -67 | -41 | -213 | -206 | -277 | -121 | -196 | -137 |
| Cash from Financing | -60 | -135 | -86 | -57 | 8 | -140 | -49 | -56 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 75 | 111 | 208 | -41 | -55 | 153 | 216 | 111 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (62.3×) and current (51.9×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At -7.9% growth and a 52× exit, ₹1827 only delivers your return if you pay ₹479. The price is currently baking in 18% growth.
EPS grows -7.9%/yr for 5 years, then fades to 6% over 2, exits at 52×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | -7.9% | 32.42 |
| FY28 | -7.9% | 29.86 |
| FY29 | -7.9% | 27.50 |
| FY30 | -7.9% | 25.33 |
| FY31 | -7.9% | 23.33 |
| FY32 | -0.9% ·fade | 23.10 |
| FY33 | 6.0% ·fade | 24.49 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.